ArticleJACC. Case reports2025
Late Stent Thrombosis After Biodegradable Polymer Everolimus-Eluting Stent in a Cancer Patient Receiving Bevacizumab.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe biodegradable polymer everolimus-eluting stent (EES) aims to enhance vascular healing by avoiding durable polymer exposure, but its safety in cancer patients remains uncertain. CASE SUMMARY: A 78-year-old man with gastric and hepatocellular carcinoma underwent percutaneous coronary intervention with implantation of a biodegradable polymer EES in the right coronary artery for acute myocardial infarction, followed by dual antiplatelet therapy. After cancer surgery, he received bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, as well as atezolizumab. On day 199 after stenting, 14 days after his second chemotherapy cycle, he died of sudden cardiac arrest. Autopsy revealed thrombotic occlusion of the stented segment, and histology showed complete re-endothelialization with abundant fibrin around the stent struts, expressing plasminogen activator inhibitor-1 with macrophages. DISCUSSION: This case illustrates late stent thrombosis despite complete re-endothelialization on the biodegradable polymer EES, suggesting that both the patient's cancer-related prothrombotic state and his anti-VEGF therapy may have overcome the theoretical safety advantage of the stent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.